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 Despite advancements in diabetes devices and management technologies, pediatric 
patients with type 1 diabetes (T1D) are still struggling to meet standards for glycemic goals. 
With the inability to appropriately control glucose levels, studies have shown that there are 
definite increases in diabetes-related complications and potentially life-threatening 
consequences.  Currently, diabetes success is measured by having a hemoglobin A1c (HbA1c) 
value that is less than or equal to the national target of 7.5%.  Recognizing that a disappointing 
percentage of patients are actually meeting these glycemic targets, researchers have attempted to 
narrow the gap between patients achieving and not achieving metabolic control.  While it has 
been suggested that the glycemic profile is not being evaluated in its entirety, this thesis project 
examined the need to integrate other metrics when evaluating a patient’s actual degree of 
glycemic control and resultant diabetes success.   
 The project focus was directed to time in range values, rather than HbA1c levels, as a 
defining outcome of glycemic control.  Data was collected on pediatric patients with type 1 
diabetes who were using continuous glucose monitoring (CGM).  Parameters such as HbA1c 
levels, time in range, average sensor glucose, scored levels of compliance to six specific self-
management behaviors, along with basic demographic information were included in the final 
data set.  The primary relationship between the effect adherence to six self-management habits 
had on time in range values was closely analyzed.   
 A final sample size of 654 T1D pediatric patients using CGM were included for review.  
Results from regression analyses indicated that patients who performed the self-management 
habits were more likely to have higher time in range values.  As patients increased their 
adherence to the six habits by performing more than one behavior, time in range values also 
iii  
increased.  In spite of the promising relationship identified between these two variables, still only 
18.8% of the CGM cohort met the current goals for time in range (≥60%).  In the same cohort, 
only 32.9% of patients met the standard HbA1c target.  Disproportionate access to CGM may 
play a role in the statistical findings of this cohort with regard to meeting glycemic targets, as 
time in range is most easily retrieved from CGM devices when evaluating metabolic control.   
 Discovering a correlation between time in range and self-management habits is only one 
of many steps to reevaluate how diabetes success is defined.  Combining time in range 
information with current HbA1c testing could facilitate the development of more realistic 
management plans for patients with type 1 diabetes.  Introducing the importance of time in range 
and its positive associations with reduced disease-related complications and improved glycemic 
control is vital to initiate a more encompassing review of diabetes success. Future research is still 
needed to further investigate the relationship between time in range and compliance with self-
management behaviors in a larger population of patients with type 1 diabetes.  Having scientific 
data to support other metrics and methods to aid in disease management could offer patients with 
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 Blood Glucose Monitoring Frequency:  at-home testing of blood glucose levels to  
  monitor for and prevent asymptomatic hypoglycemia. 
  
 Capillary glucose:  concentration of glucose in the blood. 
  
 Continuous Glucose Monitoring: advanced way for people living with diabetes to  
  check glucose readings in real-time or monitor glucose readings over a period of  
  time using a device. 
 
 Glucose Counterregulation:  the sum of processes that protect against development of  
  hypoglycemia and that restore normal glycemia if hypoglycemia should occur 
  
 Glucose Variation (GV):  the acute excursions of glucose around a mean value 
 HCL: also known as the artificial pancreas, the hybrid closed-loop system combines a  
  continuous glucose monitor and an insulin pump to regulate a user's insulin with  
  minimal interaction required from the patient. 
  
 Hemoglobin A1c (HbA1c):  a form of hemoglobin (a blood pigment that carries oxygen) 
  that is bound to glucose. 
  
 Hyperglycemia:  a condition caused by a very high level of blood sugar (glucose) 
 Hypoglycemia:  a condition caused by a very low level of blood sugar (glucose)  
 Interstitial glucose:  glucose measured from the fluid that surrounds the cells of tissue  
  below the skin. 
 
 SMBG:  an approach whereby people with diabetes measure their blood sugar   
  themselves using a glucose meter. 
  
 Time in range (TIR):  the percentage of time that a person spends with their blood  







Chapter 1. Introduction 
1.1 Background 
 Type 1 diabetes (T1D) is an autoimmune disorder in which the pancreas produces little or 
no insulin.1  “It is generally thought to be precipitated by an immune-associate, if not directly 
immune-mediated, destruction of the insulin-producing pancreatic beta cells resulting in the 
presence of autoantibodies.” 2  This means that in patients with type 1 diabetes, the immune 
system, which normally fights infection, attacks and destroys the cells in the pancreas that are 
responsible for making insulin.  Insulin is a hormone necessary to convert food into energy that 
fuels the body. Without insulin, other organs in the body struggle to function properly, which 
leads to serious complications.3 This decrease in available insulin causes blood sugar levels to 
rise.  As a result, people with T1D need to take insulin every day in order to stay alive.  The 
exact cause of this chronic condition is unknown, but it is believed that several factors may 
contribute to the onset of disease.  Genetics and exposure to viruses and other environmental 
elements that may trigger the body’s immune response are possible causes.  
 The American Diabetes Association (ADA) reports that an average of 1.5 million people 
are diagnosed with diabetes every year; 5% of which have type 1 diabetes.4,5 The risk to develop 
                                                     
1 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2017). Type 1 Diabetes. Retrieved 
from https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/type-1-diabetes#diagnose  
 
2 Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010). Genetics, pathogenesis and clinical interventions in type 1 
diabetes. Nature, 464, 1293-1300. doi:10.1038/nature08933 
 
3 American Diabetes Association. (2019, June 10). Access to Continuous Glucose Monitors in Pediatric Diabetes 
Populations Improves Glycemic Control, Reduces Hypoglycemia and Improves Satisfaction with Diabetes Care and 
Technology Use. San Francisco, CA, USA. Retrieved from https://www.diabetes.org/newsroom/press-
releases/2019/access-to-continuous-glucose 
 
4 Diabetes Research Institute Foundation. (2020). What is Diabetes? Retrieved from 
https://www.diabetesresearch.org/what-is-diabetes 
 
5 American Diabetes Association. (2020). Statistics About Diabetes. Retrieved from 
https://www.diabetes.org/resources/statistics/statistics-about-diabetes 
2  
type 1 diabetes for people in the general population is about 1 in 300. For those who have a 
family member with T1D, the risk increases to 1 in 20, or 15 times greater than that of the 
general population.6  Common symptoms of type 1 diabetes include increased thirst, increased 
urination, extreme hunger, blurred vision, weakness, fatigue, rapid and unexplained weight loss, 
unusual irritability, nausea, vomiting, abdominal pain, unpleasant breath odor, and itchy skin.6 
 The primary treatment for patients with types 1 diabetes is insulin therapy.  The ADA 
recommends that pediatric patients with T1D should be treated with intensive insulin therapy and 
should self-monitor blood glucose (SMBG) levels multiple times a day.7  While the ADA does 
not provide a concrete number of times one should check blood sugars daily, they do recognize 
and emphasize the fact that SMBG is crucial in T1D control.  Despite these management 
recommendations, treatment challenges continue to center around knowing how much or how 
little insulin to administer to correct blood sugars that are outside of a normal range. While there 
are methods to make educated calculations based on information utilizing carbohydrate ratios, 
the body's varying response to physiological changes can still make accurately dosing insulin a 
guessing game.   
 Complications resulting from uncontrolled diabetes will vary depending on the type of 
glucose excursions. Extended periods of elevated blood glucose levels, known as hyperglycemia, 
result in long-term complications and can be life-threatening.  Consistently high blood glucose 
levels can lead to other health problems such as heart disease, stroke, kidney failure, dental 
                                                     
 
6 Type 1 Diabetes TrialNet. (2020). T1D Facts. Retrieved from https://www.trialnet.org/t1d-facts 
 
7 American Diabetes Association. (2018). Children and Adolescents. Sec. 12. In Standards of Medical Care in 
Diabetes. Diabetes Care, 41(Supplement 1), S126-S136. doi:10.2337/dc18-S012 
 
3  
diseases, nerve damage, depression, sleep apnea, and vision problems.8  If high levels of blood 
glucose are left untreated, there can be further damage to the eyes, kidneys, nerves, heart, which 
can lead to coma and death.9  Low levels of blood glucose, or hypoglycemia, can result in other 
serious conditions and can also quickly become life-threatening. Hypoglycemia can result in 
many clinically relevant occurrences such as an increased risk of subsequent severe 
hypoglycemia, defective glucose counterregulation/impaired hypoglycemia awareness, 
impairment in cognitive function, increase in cardiac arrhythmias, reduced work productivity, 
and impacts on sleep and quality of life.10,11,12,13,14,15  For these reasons alone, uncontrolled 
diabetes is not a viable option. 
 The current clinical guideline to determine if a pediatric patient is in control of their 
                                                     
8 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2017). Type 1 Diabetes. Retrieved 
from https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/type-1-diabetes#diagnose 
 
9 If high levels of blood glucose are left untreated, there can be damage to the eyes, kidneys, nerves, and the heart, 
and can also lead to coma and death.  
 
10 Brod, M., Christensen, T., Thomsen, T. L., & Bushnell, D. M. (2011). The Impact of Non-Severe Hypoglycemic 
Events on Work Productivity and Diabetes Management. Value in Health, 14(5), 665-671. 
doi:10.1016/j.jval.2011.02.001 
 
11 Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. (2011). Factors Predictive 
of Severe Hypoglycemia in Type 1 Diabetes. Diabetes Care, 34, 586-590. doi:10.2337/dc10-1111 
 
12 Brod, M., Pohlman, B., Wolden, M., & Christensen, T. (2013). Non-severe nocturnal hypoglycemic events: 
experience and impacts on patient functioning and well-being. Quality of Life Research, 22, 997-1004. 
doi:10.1007/s11136-012-0234-3 
 
13 Seaquist, E. R.,  Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., . . . Vigersky, R. (2013). 
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine 
Society. The Journal of Clinical Endocrinology & Metabolism, 98(5), 1845–1859. doi:10.1210/jc.2012-4127 
  
14 International Hypoglycaemia Study Group. (2017). Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) 
Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the 
European Association for the Study of Diabetes. Diabetes Care, 40(1), 155-157. doi:10.2337/dc16-2215 
 
15 Fawdry, R. A., Novodvorsky, P., Bernjak, A., Chow, E., Iqbal, A., Sellors, L., . . . Heller, S. R. (2017). Diurnal 
Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 
Diabetes. Diabetes Care, 40(5), 655-662. doi:10.2337/dc16-2177 
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diabetes, set by the American Diabetes Association and the International Society for Pediatric 
and Adolescent Diabetes, is maintenance of a hemoglobin A1C (HbA1c) value less than 7.5%.16  
Most children with type 1 diabetes have HbA1c values well above target levels.  There appears 
to be increasing support in declaring that glycemic goals may not be universal and that goals 
customized to each case may be more appropriate.  “In those individuals with diabetes who are at 
risk for iatrogenic hypoglycemia because of treatment with insulin or other glucose lowering 
medications, a reasonable glycemic goal should be the lowest HbA1c that does not cause severe 
hypoglycemia at any given stage in the evolution of the individual's diabetes”.17  A range of 
acceptable HbA1c values, rather than one specified value, may be a better approach to using 
HbA1c as a metric to define diabetes success.  Furthermore, there are known limitations to 
HbA1c testing that may interfere with accurate depictions of the glycemic profile and play a role 
in defining a patient’s level of control of their disease. 
 Aside from striving to continually meet glycemic targets, patients with type 1 diabetes 
and their care providers face many challenges related to disease management.  Given the 
complexity of the condition, patients and providers must be mindful of proper nutrition, levels of 
exercise, dedication to self-monitoring and accurate reporting, continuing education for devices, 
adherence to management plans, attending regular clinic visits, and the ongoing issues related to 
insurance coverage and affordability of necessary medications and supplies.18  “The management 
                                                     
16 Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., . . . Tamborlane, W. 
V. (2015). Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic 
Registry. Diabetes Care, 38(6), 971-978. doi:10.2337/dc15-0078 
 
17 Cryer, P. E. (2014). Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic 
Hypoglycemia. Diabetes, 63(7), 2188-2195. doi:10.2337/db14-0059 
 
18 Iyengar, J., Thomas, I. H., & Soleimanpour, S. A. (2019). Transition from pediatric to adult care in emerging 




of pediatric type 1 diabetes requires the daily execution of a complex and demanding set of 
health behaviors, including but not limited to the coordination of the amount and timing of 
insulin administration with results of blood glucose monitoring, the amount and type of dietary 
intake, and the frequency and intensity of physical activity.”19  Patients with T1D cannot avoid 
disease-related complications by using exogenous insulin alone.  Because of this, management 
plans often include the use of devices such as insulin pumps, hybrid closed loop systems (HCL), 
and other types of glucose meters to aid with optimal metabolic control.20   
 One device system in particular, continuous glucose monitoring (CGM), is able to 
overcome limitations of traditional blood glucose checks by providing a real-time picture of the 
glucose profile which grants T1D patients an opportunity to intervene when necessary to make 
immediate adjustments in order to prevent extreme glycemic events.21  “CGM measures 
interstitial glucose (which correlates well with plasma glucose) and includes sophisticated alarms 
for hypo- and hyperglycemic excursions.”22  The system uses glucose sensors that are inserted 
subcutaneously with the attached device being worn externally by the patient.  CGM allows for 
constant observations of glycemic events which can provide the opportunity for patients to make 
treatment adjustments in real-time.  This type of monitoring can identify patterns and glucose 
variability, in addition to providing valuable information on not only current glucose levels but 
                                                     
19 Vesco, A. T., Anderson, B. J.,  Laffel, L. M., Dolan, L. M., Ingerski, L. M., & Hood, K. K. (2010). Responsibility 
Sharing between Adolescents with Type 1 Diabetes and Their Caregivers: Importance of Adolescent Perceptions on 
Diabetes Management and Control. Journal of Pediatric Psychology, 35(10), 1168–1177. doi:10.1093/jpepsy/jsq038 
 
20 Aatkinson, M., Seisenbarth, G., & Wmichels, A. (2014). Type 1 diabetes. The Lancet, 383(9911), 69-82. 
doi:10.1016/S0140-6736(13)60591-7 
  
21 Alarcon-Casas Wright, L., & Hirsch, I. B. (2017). Metrics Beyond Hemoglobin A1C in Diabetes Management: 
Time in Range, Hypoglycemia, and Other Parameters. Diabetes Technology & Therapeutics, 19(Supplement 2), 
S16-S26. doi:10.1089/dia.2017.0029 
  
22 American Diabetes Association. (2017). Glycemic targets. Sec. 6. In Standards of Medical Care. Diabetes Care, 
40(Supplement 1), S48-S56. doi:10.2337/dc17-S009 
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also rates of change in those levels and associated trends.23  “CGM profiles provide far more 
information than just the mean glucose variations.  They identify patterns of hyperglycemia and 
hypoglycemia as well as potentially dangerous high or low glucose concentrations that are often 
missed with self-monitoring blood glucose (SMBG) checks.”24  Studies have shown that CGM 
systems can decrease the amount of time spent in hypoglycemia stages and lower HbA1c levels, 
and are considered to be very effective devices to regulate glucose levels, as long as patients are 
willing to wear them and maintain them properly.25  
 In 2017, roughly 11% of the type 1 diabetes community were using CGMs, but the rate is 
still slowly increasing.26  CGM is becoming more popular because of the system’s ability to 
rapidly aid in decision making regarding insulin dosing.  Another added benefit is the utilization 
of convenient alarm features that provide early warning of abnormal glucose levels which helps 
limit the potential for more severe glycemic events.  More recently, CGM has been advantageous 
to new clinical uses to close loops between insulin pumps.  “CGM profiles provide opportunities 
to develop measures of glycemic control that provide clinically beneficial information beyond 
that provided by a HbA1c value and periodic self-testing of capillary glucose.”27  Such metrics 
                                                     
23 Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., . . . Phillip, M. (2019). Clinical 
Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International 
Consensus on Time in Range. Diabetes Care, 42(8), 1593-1603. doi:10.2337/dci19-0028 
 
24 Beck, R. W., Connor, C. G., Mullen, D. M., Wesley, D. M., & Bergenstal, R. M. (2017). The Fallacy of Average: 
How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading. Diabetes Care, 40(8), 994-999. 
doi:10.2337/dc17-0636 
 
25 Aatkinson, M., Seisenbarth, G., & Wmichels, A. (2014). Type 1 diabetes. The Lancet, 383(9911), 69-82. 
doi:10.1016/S0140-6736(13)60591-7 
 
26 Agiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., . . . Weinzimer, S. A. (2017). 
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report 
of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the 
American Diabetes Association, the Endo. Diabetes Care, 40(12), 1622-1630. doi:10.2337/dc17-1624 
 
27 Riddle, M. C., Gerstein, H. C., & Cefalu, W. T. (2017). Maturation of CGM and Glycemic Measurements Beyond 
HbA1c—A Turning Point in Research and Clinical Decisions. Diabetes Care, 40(12), 1611-1613. 
7  
are glucose exposure, glucose variation (GV), standard deviation (SD) round mean glucose, and 
time in range (TIR).  CGMs are ideal and more accurate for reporting time in range because they 
collect constant measurements (usually every five minutes) that portray the full picture of 
precisely how many hours each day are spent within target glycemic ranges.28  Ideally, CGM 
data is collected for “at least 14 days immediately preceding the measurement of HbA1c during a 
period when diabetes treatment and glycemic control are reasonably stable.”29 
 
1.2 Statement of the Problem 
 Because patients with diabetes are not meeting their glycemic goals, attention is being 
redirected to the use of quality improvement (QI) methods for not only improving clinical care 
but also patient outcomes.  Previous research conducted using data from registries has shown 
that compliance with self-management habits aids in improving glycemic outcomes.  This thesis 
project aims to transition a similar type of attention to a clinical setting.  As diabetes treatment 
technologies advance, more information related to glucose metrics is becoming available.  It is 
clear that HbA1c testing as a means to evaluate diabetes control may not be as widely accepted 
anymore, as there are limitations to the test itself that may not fully reflect a patient’s typical 
glucose profile.  One of the most concerning limitations of HbA1c measurements is the inability 
for the test to detect low blood glucose levels.30  Low blood glucose, or hypoglycemia, can result 
                                                     
doi:10.2337/dci17-0049 
 
28 diaTribe Foundation. (2020). Time in Range. Retrieved from https://diatribe.org/time-range 
 
29 Xing, D., Kollman, C., Beck, R. W., Tamborlane, W. V., Laffel, L., Buckingham, B. A., . . . Ruedy, K. J. (2011). 
Optimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring. 
Diabetes Technology & Therapeutics, 13(3), 351-358. doi:10.1089/dia.2010.0156 
 
30 Runge, A. S., Kennedy, L., Brown, A. S., Dove, A., Levine, B. J., Koontz, S., . . . Wood, R. (2018). Does Time-
in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of 
Improved Outcomes. Clinical Diabetes, 36(2), 112-119. doi:10.2337/cd17-0094 
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in many clinically relevant occurrences and have a negative impact on one’s quality of life.   
Given the limitations of HbA1c testing, other diabetes metrics should be considered when 
defining optimal glucose control for pediatric patients with type 1 diabetes.  
 One such metric coming to the forefront of gauging successful diabetes is time in range 
(TIR).  TIR is the percentage of time that a person spends with their blood glucose levels in a 
specified target range.  TIR more accurately presents profiles for individuals who have blood 
glucose levels rarely outside of their defined thresholds.  Patients who have glucose levels more 
in range are less likely to experience short-term or long-term health effects than those who have 
more frequent blood glucose excursions.31  A more accurate review of glucose profiles will allow 
clinicians to make appropriate adjustments in the diabetes management plan resulting in better 
glycemic control and quality of life for patients suffering from type 1 diabetes.  Research is 
needed to evaluate relationships between TIR and compliance with self-management habits to 
ensure that the associations between TIR and self-management behaviors are similar enough to 
HbA1c and self-management behaviors for comparative outcomes of diabetes success. 
 
1.3 Research Question 
 Studies have demonstrated that self-management habits such as frequent self-monitoring 
of blood glucose, using devices such as continuous glucose monitoring and insulin pumps, 
frequent insulin bolusing, and reviewing diabetes data are associated with improved glycemic 
                                                     
 
31 Agiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., . . . Weinzimer, S. A. (2017). 
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report 
of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the 
American Diabetes Association, the Endo. Diabetes Care, 40(12), 1622-1630. doi:10.2337/dc17-1624 
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outcomes.32,33,34,35 As more attention within the diabetes community becomes focused on 
discovering better metrics for defining successful diabetes management, the concentration for 
this thesis project resided in investigating a more elementary question to that argument:  In 
pediatric patients with type 1 diabetes who use a continuous glucose monitor, is there a 
relationship between adherence to self-management behaviors and attaining time in range 
targets? 
 
1.4 Research Objectives 
 
 The objective of this study was to evaluate the relationship of six specific self-
management habits performed by people with type 1 diabetes and to assess the association with 
optimal glycemic outcomes as measured by time in range values.  The primary outcome was 
initially to identify a positive relationship between time in range values and several key 
adherence behaviors which would be used to suggest that TIR is another glycemic metric that 
should be more seriously considered when evaluating the status of a patient’s level of metabolic 
control. 
 
                                                     
32 Rausch, J. R., Hood, K. K., Delamater, A., Pendley, J. S., Rohan, J. M., Reeves, G., . . . Drotar, D. (2012). 
Changes in Treatment Adherence and Glycemic Control During the Transition to Adolescence in Type 1 Diabetes. 
Diabetes Care, 35, 1219-1224. 
 
33 McNally, K., Rohan, J., Shroff Pendley, J., Delamater, A., & Drotar, D. (2010). Executive Functioning, Treatment 
Adherence, and Glycemic Control in Children With Type 1 Diabetes. Diabetes Care, 33(6), 1159-1162. 
doi:10.2337/dc09-2116 
 
34 Hilliard, M. E., Wu, Y. P., Rausch, J., Dolan, L. M., & Hood, K. K. (2013). Predictors of Deteriorations in 
Diabetes Management and Control in Adolescents With Type 1 Diabetes. Journal of Adolescent Health, 52(1), 28-
34. doi:10.1016/j.jadohealth.2012.05.009 
  
35 Ziegler, R.,  Heidtmann, B., Hilgard, D., Hofer, S., Rosenbauer, J., & Holl, R. (2011). Frequency of SMBG 
correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatric Diabetes, 




 If time in range proves to be a valid measure of glycemic control, recommendations 
could be made to modify the types of data collected from patients with diabetes.  For instance, 
rather than basing management decisions solely on HbA1c data, patients and providers could 
efficiently review time in range and other metrics available from diabetes devices to more 
accurately make adjustments to treatment and behavior regimens.  To take things one step 
further, one might even go as far to imply that time in range not only be used as a 
complementary method to HbA1c when evaluating diabetes control, but rather that it should be 
used as a primary metric for assessing diabetes success.  The way in which glycemic profiles are 
presented and reviewed by patients and their care teams could be impacted if data supports 




Chapter 2. Literature Review 
 
2.1 Overview 
 Online searches for publications via PubMed and Google Scholar through access 
provided by the University of Michigan was the principal method utilized for the literature 
review.  Both databases house millions of scholarly sources for biomedical texts.  Primary 
searches involved key words such as type 1 diabetes, time in range, metrics, hemoglobin HbA1c, 
glycemic control, glycemic targets, and continuous glucose monitors.  Information was gathered 
from sources that reviewed any combination of the main search criteria.  Results were restricted 
to articles published within the last ten years.  Studies that reported relationships between 
diabetes metrics, glycemic targets, management behaviors, and/or limitations to current metrics 
and testing were included for review.  Additional searches were performed from reference lists 
when appropriate.  Less structured searches related to general diabetes knowledge were also 
performed. 
 In general, the literature highlighted five major topics concerning glycemic control in 
pediatric patients with type 1 diabetes.  Self-management habits and the use of diabetes devices, 
HbA1c and its limitations, benefits of incorporating time in range, relationships between various 
behaviors and glycemic metrics, and issues surrounding the inability to meet standardized 
glycemic targets were among the discussions.  With this final factor highlighting concerns 
among clinicians and researchers that comprehensive glycemic profiles should be considered 
rather than snapshots of a T1D patient’s spectrum, it seemed fitting for this project to investigate 
the potential of introducing new metrics for evaluating a patient’s level of glucose control and 
successful disease management. 
  
12  
2.2 Details of Review 
 Diabetes is known to be a chronic and potentially disabling disorder that represents a 
major clinical and public health concern.  Constantly attempting to regulate blood glucose levels 
in order to prevent serious complications is critical to patients with type 1 diabetes.  Research has 
shown that there are ways for patients to actively participate in the daily management of their 
diabetes by performing several behavioral habits.  The American Diabetes Association’s 
recommendation of at least four blood glucose checks daily is supported by Hillard's findings 
that patients who met their glycemic targets completed 1-2 more glucose checks per day than 
patients who were out of target ranges.36  Blood glucose checks often consist of a finger poke, 
which provides a small sample of blood that can be tested using at-home glucometers.  “The 
frequency of blood glucose monitoring, which is readily available information to clinicians, 
offers a powerful tool for targeted management of type 1 diabetes, especially when combined 
with data concerning recent trajectories of glycemic control”.37   
 Adherence to this portion of a treatment plan can be affected by a variety of factors, such 
as an individual's social situation, access to resources, levels of stress or diabetes-related distress, 
etc.  Non-adherence with self-monitored blood glucose checking often occurs by way of the 
reduced frequency of checks or misreporting blood glucose values, either verbally or via 
logbooks submitted to care teams.38 Misreporting of self-monitored blood glucose (SMBG) often 
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occurs to present a more favorable management profile. Studies have shown that 75% of patients 
misreport their blood glucose levels by documenting lower values than actually recorded by the 
glucometer.39 
 Not only do T1D patients have to perform SMBG, they also need to respond to the 
displayed results accordingly.  It has been reported that patients with T1D who check blood 
glucose levels at least once per day do not always make adjustments to their management habits 
when levels are extremely high or too low.40  Patients need to be educated in knowing when to 
intervene and what action is most appropriate depending in the reading from their glucometer. 
 Although there is substantial support presented by Rausch and colleagues for blood 
glucose monitoring frequency (BGMF) being used as an objective measure for treatment 
adherence in pediatric type 1 diabetes, they go on to propose that BGMF may not fully capture 
the multidimensional nature of treatment adherence.41  In an effort to collect more 
comprehensive data related to treatment adherence, this thesis project focused on six behavioral 
self-management habits instead of just BGMF alone.  Becoming more open to newer trends and 
updated approaches to manage type 1 diabetes is the first step in making positive changes to 
achieve glycemic targets.42  The literature suggested that patients can use CGM information to 
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better detect patterns and make appropriate adjustments to their treatment plans.43  
 “Continuous glucose monitoring (CGM) is a method of continuously following glucose 
levels in the interstitial fluid as a basis for improving metabolic control”.44  CGM reported in a 
standardized way has the potential to help clinicians empower patients and decrease the burden 
of living with diabetes and its complications.45  This method of monitoring blood glucose levels 
is also less cumbersome to the patient since they are not required to perform independent finger 
checks as often given the CGM’s built-in capability of frequent interstitial testing which relays 
information to other synchronized devices.  This constant observation of blood glucose levels 
allows CGMs to easily determine if an HbA1c value is over-or-underestimating the actual level 
of glycemic control.46 
 Rates for CGM usage have been steadily increasing.  “Use of CGM increased from 7% in 
2010–2012 to 30% in 2016–2018, with an exponential increase in use beginning between years 
2013 and 2014. Children had a >10-fold increase in CGM use (4%–51% in children <6 years old 
and 3%–37% in children 6–12 years old)”.47  However, despite its usefulness in managing 
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diabetes, research continues to show that CGMs are still widely underused.48  As with many 
things, there are limitations to CGM usability.  Limitations may include but are not limited to: 
issues related to technology (calibrations, sensor expiration), user compliance (patients must 
actually wear the devices, avoidance of skin puncture), safety (skin reactions, devices becoming 
detached, losing transmitter/receiver), and costs (not covered by all insurance companies, some 
require prior approval/paperwork, out-of-pocket costs associated with 
supplies/replacements/repairs).49 It is important to note that research still needs to be conducted 
to assess the full range of efficacy of diabetes therapies, like CGM, given the limitations to the 
availability and usage of certain devices.50  Until more data is available, hemoglobin A1c 
(HbA1c) remains the current standard for glycemic control. 
 Discovered in 1968, hemoglobin A1c was first used for clinical care in the early 1980s.51  
“Hemoglobin A1c became the gold-standard for assessing glycemic management after the 
landmark Diabetes Control and Complications Trial (DCCT) demonstrated the strong association 
between HbA1c levels and the risk of chronic diabetic vascular complications.  Laboratory 
methods were soon developed so that HbA1c levels could be readily measured with a reasonable 
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degree of precision”.52  HbA1c tests measure the amount of glycosylated hemoglobin in the 
blood which is currently the metric of choice for assessing the efficacy of new diabetes products, 
guiding health care providers' choice of medications, and supporting regulatory approval and 
reimbursement policies.53, 54   
 “HbA1C, in the setting of a normal hematological profile and in the non-pregnant 
population, reflects mean glucose value over the previous 8-12 weeks”. 55  There is variation 
among HbA1c and glucose concentrations and it is likely the result of the variability in the red 
blood cell life spans.56  Hence, HbA1c levels can be affected by conditions that affect the life 
span of red blood cells. For instance, untreated iron deficiencies will yield falsely high HbA1c 
levels; hemolysis, splenomegaly, and some medications will result in falsely low HbA1c levels.  
These values are independent of true glycemia.  HbA1c can also be affected by stressful events 
that temporarily lessen glycemic control, which is another concept to consider as this is not 
reflective of real diabetes control.  It has also been recognized that many clinical situations could 
result in falsely low (and occasionally falsely high) HbA1c levels.57  Given this knowledge, it 
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can be presumed that HbA1c is not always a true reflection of glucose profiles because its 
accuracy can be compromised by many variables affecting the survival of red blood cells. 
 “As a measure of mean blood glucose over a two to three-month period, HbA1c does not 
capture short-term variations in blood glucose or exposure to hypoglycemia and hyperglycemia 
in individuals with type 1 diabetes; HbA1c also does not capture the impact of blood glucose 
variations on an individual's quality of life”.58  Because glycemia is a complex process, clinical 
interpretations of redundant mechanisms that rely on glucose as an energy source may be another 
limitation to HbA1c.52  Connections have been made to the limitations of HbA1c testing and the 
lack in accuracy to reflect a patient’s complete glycemic profile.59,60,61   
 Another limitation to using HbA1c as the metric determining metabolic control lies in the 
fact that there can be wide ranges of glucose concentrations for a given HbA1c value.  Studies 
have shown a range of approximately 80 mg/dL in average glucose values for the same HbA1c 
value.62  This means that an HbA1c of 8% could be associated with average glucose levels 
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between 128-249 mg/dL.63  Metabolic control as indicated by average HbA1c levels can vary 
significantly among different treatment regimens, with differences also being observed in HbA1c 
relationships between individuals within ethnic groups.64,65  This inter-individual variability that 
exists in the relationship between HbA1c and mean glucose concentrations indicates that HbA1c 
may not be a great indicator of control for every patient.  These facts regarding the limitations 
with HbA1c testing are prime examples of why additional metrics should be considered when 
defining real glycemic control.   
 After investigations into standardizing clinically meaningful diabetes-related outcomes 
were concluded, researchers did not insist that other outcomes replace current HbA1c standards 
for glucose control, but rather suggested that other metrics be used to supplement the limitations 
of HbA1c and include outcomes that incorporate other glucose profiles that can provide a more 
comprehensive understanding of the full picture.66  Studies have shown that patients with the 
same HbA1c value had different rates of microvascular complications, prompting the 
endocrinology community to research metrics, other than HbA1c, for assessing glycemic control 
to reduce both short and long-term diabetes-related complications.67  Cryer's research further 
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implied that HbA1c goals should be individualized and that higher HbA1c targets may be more 
fitting for some patients with T1D.68  Because HbA1c cannot provide information related to 
glucose variations, there is need for additional measurable outcomes for T1D patients.  These 
notions appear to echo the general consensus that HbA1c should not be the sole focus when 
defining successful T1D management and glycemic control because of the reality that HbA1c 
goals will vary between patients.   
 “With the advent of new technologies to assess glycemia, recent evidence linking 
hypoglycemia with adverse outcomes, and the increased knowledge on the limitation of HbA1c 
and SMBG, new metrics need to be incorporated to better understand the dynamic nature of 
glucose, how to help patients achieve optimal control, and ways to reduce complications”.64 
Time in range (TIR) is one such metric.  Authors indicated that there is interest in the diabetes 
community to define measures of glycemic control aside from HbA1c that may include TIR or 
revised classifications of hypoglycemia.69  Time in range is the percentage of time that a person 
spends with their blood glucose levels in a target range.  It can be calculated by using the 
following formula:   
 
Time in Range (%)  =     number of blood glucose values within specific range  x 100 
                        total number of blood glucose values 
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 The range will vary depending on the individual, but general guidelines suggest starting 
with a range of 70 to 180 mg/dL.70 “Target range and time in range can be expressed either as 
"% of glucose reading" or "hours per day".  The proposed target range of 70-180 mg/dL was 
considered acceptable for clinical practice, as it has been observed that if 50% of the SMBG 
readings are in such range, HbA1c would be around 7%”.71  The average person with type 1 
diabetes has a time in range of roughly 50-60%.66  Range definitions for TIR are kept wide to 
allow for variations across the T1D population.   
 “Time in range captures fluctuations in glucose levels continuously, whereas HbA1c 
testing is done at static points in time”.72  Since TIR can be measured anywhere at any time (via 
diabetes devices) there is a large advantage in having the capability to study the times of day or 
choices made by the patient that yielded better TIR percentages.  This feature allows a patient to 
look in real time at what actions directly elevated and reduced blood glucose levels, and provides 
the opportunity to make changes to better control glycemic excursions.  Time in range provides a 
more simplistic view of the "cause-and-effect" relationship of T1D and is presented in a manner 
that is easily understood by both patient and provider.  Time in range gives T1D patients more 
control of their diabetes because of the convenience to access up-to-date information and make 
adjustments as necessary.  “Some researchers believe that time in range serves as a better 
predictor of complications, since it is a direct measure of glucose in the blood vessels.  
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Conversely, HbA1c is an indirect measure of blood glucose since it is dependent on the turnover 
of red blood cells”.66   
 Time in range is also more specific and sensitive than current HbA1c testing.  It more 
accurately presents profiles for individuals who have blood glucose levels rarely outside of their 
defined thresholds.  Patients who are more in range are less likely to experience short-term or 
long-term health effects than those who have more frequent blood glucose excursions.73  As a 
result, it is more representative of the patient’s entire glycemic profile.  TIR helps providers 
know what areas of the management plan need to be focused on more closely to better improve 
metabolic control.  Hirsch and his team stated that patients and providers agreed that using TIR 
as a primary metric for disease control is more accurate and is easier for most people to 
understand and use the data to make necessary adjustments quickly.74 
 Another advantage to reviewing TIR is that “time in range percentages are more likely to 
be comparable across patients that HbA1c values, which often have patient-specific variations in 
significance”.75  The specificity of time in range can be best understood by comparing variations 
in glucose levels throughout a 24-hour period in T1D patients that all have the same HbA1c and 
average blood glucoses.  Figure 1 is a visual representation of TIR that demonstrates how it can 
vary between patients with other identical glycemic metrics.  As one can see, time in range has 
the ability to highlight differences in real glycemic control and the variances that HbA1c cannot 
capture.  
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 Researchers have deemed TIR to be a solid metric of glycemic control that presents 
actionable data.76  It provides applications on both a patient level by providing opportunities to 
make immediate adjustments to treatment and management behaviors, and on a provider level by 
presenting a clear picture of severe glucose excursions.  A study conducted by Runge and 
collaborators showed that time in range was the highest ranking outcome believed to have the 
largest impact on daily life for patients with type 1 diabetes.  Time in range emerged as the top 
outcome measure that both reflects patients' priorities and can be used to quantitatively evaluate 
treatment efficacy.77  Patients with type 1 diabetes clearly recognize the value of TIR and the 
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impact that it has on their daily struggle with glycemic control.  Time in range is a great 
complement to HbA1c and should be considered an integral aspect of daily decision making for 
patients with type 1 diabetes.78 
 Limitations for time in range are less biological than those noted for HbA1c.  The most 
obvious limitation is the ability to access and use diabetes devices like CGM.  If a patient is 
unable or unwilling to use a diabetes device to continually check blood glucose levels throughout 
the day, then a patient would need to manually perform glucose monitoring.  Not only would 
patients without devices need to physically perform the blood glucose checks, but they would 
also have to record it, often in the form of a log book.  The rates of noncompliance with self-
monitoring blood glucose frequencies are already an obstacle, and research has shown various 
reasons how and why patients are noncompliant with accurately reporting blood glucose levels to 
providers. 
 A majority of the associations made among diabetes-related metrics and glycemic 
outcomes appeared to center around general adherence to treatment plans, performance of self-
management habits like blood glucose monitoring frequency, use of diabetes devices such as 
CGMs or insulin pumps, and time in range.  A general summary of the relationships is presented 
in Table 1.  With regard to general treatment adherence, researchers found that a pediatric 
patient's adherence to treatment regimens resulted in better glycemic control thereby making 
glycemic control dependent on treatment adherence.79  Throughout the literature, “blood glucose 
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monitoring frequency (BGMF) was often chosen as an indicator of treatment adherence given its 
central role in diabetes management and its robust association with glycemic control in multiple 
studies”.80 
 Data analyzed by Rausch and associates suggested that increased numbers of daily blood 
glucose checks did predict better glycemic control and could be used as a tool for self-
management to achieve target goals.81  “Although improvement of glycemic control can result in 
significant risk reduction for future diabetes-related complications, suboptimal glycemic control 
has major consequences on long-term health outcomes”.82  More frequent self-monitoring blood 
glucose (SMBG) is also associated with better metabolic control which can reduce occurrence of 
complications from poorly controlled diabetes.80  This discovery is most important for pediatric 
patients because they will have diabetes longer than adults who are diagnosed later in life.   
In a database inclusive of approximately 27,000 pediatric patients with T1D, increased daily 
frequency of self-monitoring blood glucose (SMBG) was associated with a 0.2% lower HbA1c 
value and a decreased presence of diabetes-related complications.83  One such complication 
mentioned was diabetic ketoacidosis, or DKA, which was inversely related to SMBG 
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 Strong relationships were also identified between an increase in blood glucose 
monitoring frequency and HbA1c levels.  Self-measurement of blood glucose (SMBG) was 
associated with up to 0.5% improvement in HbA1c values with each additional check, up to a 
maximum of 5-6 checks per day.85  SMBG frequency was associated with better metabolic 
control with a decrease of 0.2% in HbA1c levels for each additional check per day.  Interestingly 
enough, increasing SMGB checks above 5 per day did not result in further HbA1c 
improvement.81   
 A recent quality improvement project conducted by University of Michigan QI Initiative 
demonstrated that in addition to SMBG, adherence to other self-management habits were 
associated with improved glycemic outcomes as measured by HbA1c.  The study evaluated the 
relationship between six specific self-management habits and HbA1c.  Habits concentrated on 
the use of CGM or SMBG frequency, administration of at least three insulin doses throughout 
the day or use of an insulin pump, the timing of which insulin was given (either before or after a 
meal), completing reviews of blood glucose data for patterns and making adjustments to the 
insulin regimen at least once since the previous diabetes clinic visit.  The findings suggested that 
performance of these behavioral habits were associated with decreased HbA1c levels with the 
largest decrease in HbA1c values being observed in patients that performed multiple behaviors.86  
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 For patients who used diabetes devices such as continuous glucose monitors (CGM) or 
insulin pumps, reported HbA1c levels were lower than those of patients who did not use devices 
as a part of their daily management plan.87  Data also showed that time in range is increased 
when insulin dosing decisions are made using information obtained from a CGM versus values 
reported from conducting SMBG checks.88 
 Lastly, there have been several links made between time in range and HbA1c.  In fact, 
“there is a good correlation between HbA1c and time in range percentages that may permit the 
transition to TIR as the preferred metric for determining the outcome of clinical studies, 
predicting the risk of diabetes complications, and assessing of an individual patient's glycemic 
control”.89  These metrics are inversely related and for every 10% change in TIR there is a 0.5%-
0.8% change in HbA1c.90  With respect to the relationship between time and range and HbA1c, 
TIR remained comparable with HbA1c across a broad range of patients with diabetes of varying 
demographics and technologies used for management.  
 Connections between time in range and associated complications of type 1 diabetes have 
also been identified.  In particular, time in range is strongly associated with risk of microvascular 
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complications; TIR is lower in those who develop microvascular complications than those who 
do not.   Time in range has been found to have an association specifically with the risk of 
development or progression of retinopathy and development of microalbuminuria (MA); the 
presence of MA indicates endothelial dysfunction which can result in other cardiovascular events 
or death. 91  “Research shows that with each 10% drop in TIR, there is an increase in risk of 
retinopathy by 64% and of microalbuminuria by 40%”.92  In general, as time in range increases, 
diabetes complications decreases. 
 
Table 1. Diabetes management and metrics relationships 
Variables Correlation Relationship Trends 
BGMF + Metabolic Control Positive  
BGMF + T1D Complications Negative  
BGMF + HbA1c Negative  
Adherence + Metabolic Control Positive  
Device Use + HbA1c Negative  
Device Use + TIR Positive  
TIR + Complications Negative  
TIR + HbA1c Negative  
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 It is important to note that “glycemic control is not a valid proxy for treatment adherence.  
This means that clinicians that obtain above-target HbA1c values for a particular patient and 
assume poor treatment adherence are likely to miss other relevant contributors to glycemic 
control such as dosing, timing of insulin administration, and variability of blood glucose 
monitoring”.93  This idea only stresses the importance of reviewing metrics other than HbA1c 
when gauging diabetes success.   
 When assessing glycemic targets, the ADA states that HbA1c goals should be less than 
7.5% across all age groups.94  “While there have been significant improvements in insulin 
analogs and insulin delivery systems, such as continuous subcutaneous insulin infusions with 
insulin pumps, continuous glucose monitoring, and closed loop systems, normal glucose control, 
particularly in children, is rarely achieved”.95  In fact, Wood and colleagues found that the age-
specific ADA HbA1c target was actually only met by approximately 32% of patients.96  When 
reviewing success for meeting time in range targets, it is helpful to know that for patients 
younger than 25 years of age, an HbA1c goal of less than 7.5% translates to a time in range 
target around 60%.97  Unlike HbA1c goals, TIR targets can be flexible depending on the patient's 
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individual relationship to type 1 diabetes.  For instance, pregnant women will have different 
needs and ideal glucose ranges than a patient who has had controlled diabetes for several years.91   
 “Improved insulin pumps and blood glucose meters, continuous glucose monitoring 
devices, and integrated sensor-augmented insulin pump systems with automatic threshold 
suspend capabilities have provided clinicians and patients with new tools to achieve target 
HbA1c levels more readily and safely”.98  A therapeutic intervention is considered effective if 
the improvement of HbA1c is greater than 0.4%, or the corresponding increase in TIR is 
approximately 5%.99  “Many adolescents with type 1 diabetes meet treatment goals; however, 
nearly two-thirds engage in suboptimal diabetes management and have an out-of-range glycemic 
control”.100   This may be suggestive that HbA1c targets should not be the sole predictor of 
glycemic control or a patient’s level of success with managing their diabetes.  “In selecting 
glycemic goals, the ADA recommends that the long-term health benefits of achieving a lower 
HbA1c should be balanced against the risks of hypoglycemia and the developmental burdens of 
intensive regimens in children and youth”.101  This statement is a nice segue to the proposition to 
consider other non-HbA1c metrics to determine metabolic control.  Patients and providers should 
utilize the technology as well as all of the information available to them to determine the optimal 
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approach for diabetes management, as the approach will vary by each patient and their specific 
needs and abilities.102  In order to set realistic goals, patients and providers must openly 
communicate expectations and the likelihood of a patient's ability to achieve said targets. 
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Chapter 3. Needs Assessment 
 
3.1 Assessment of Need 
 It is evident that one of the larger challenges facing patients with type 1 diabetes is 
achieving glycemic targets.  Sadly, only about 17% of children and adolescents with type 1 
diabetes are meeting the American Diabetes Association’s HbA1c goal.103  Similarly, the data 
collected for the UM QI Initiative shows that in the UM pediatric endocrinology clinic 
population only 25.6% of patients are meeting the ADA HbA1c goal.  There is a slight increase 
attaining the national HbA1c goal in patients who use CGM (see Table 2).  This inability to meet 
glycemic targets can have severe implications for a patient’s incidence of diabetes-related 
complications, and overall quality of life.  In hopes of addressing these disparities in attaining 
glycemic goals, the current project considered whether metabolic success is being accurately 
evaluated, or if there was a need to shift focus on glycemic metrics and outcomes for T1D 
patients.  If more focus becomes placed on time in range as a metric defining true glycemic 
control, then patients could be better informed to make adjustments to treatment, thereby 
improving metabolic control.  As a result, we would expect a greater percentage of patients 
meeting glycemic targets. 
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 The metrics applied to this thesis project were derived primarily from the study 
conducted by the UM QI Initiative in 2019 which revealed that HbA1c levels improved as UM 
patients with T1D adhered to six specific self-management habits. Similar to the QI study, the 
measures used for this project evaluated whether the patient uses CGM or checks blood glucose 
four times per day, gives three of more insulin injections per day, uses an insulin pump, gives 
insulin before eating, reviews blood glucose data at least once between diabetes clinic visits, and 
makes adjustments to insulin doses at least once between diabetes clinic visits.  Additional 
feedback from UM faculty advisors also indicated interest in conducting research to see if a 
similar relationship between those same six habits and time in range existed.  Insight from UM 
and JHU faculty advisors and results from an extensive literature review appeared to align with 
the need for this thesis investigation. 
  
3.3 Sources 
 UM QI Data Repository provided the initial data collected from the UM pediatric 
endocrinology clinic.  HbA1c values were collected from 1,212 unique patients receiving care in 




HbA1c ≤ 7.5% (n) 310 246
% Meeting HbA1c Target 25.6* 34.2*
Time in range ≥ 60% (n) - 124
% Meeting TIR Target - 17.2
Table 2.  Glycemic targets for UM pediatric T1D patients
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used to collect information regarding performance of the six specific self-management habits.  



































Chapter 4. Project Description 
   
 The University of Michigan Pediatric Diabetes clinic is part of the T1D Exchange 
Quality Improvement Collaborative (T1DX QIC), a quality improvement (QI) initiative of 
multiple diabetes care centers that was formed to improve outcomes for people with T1D, 
particularly glycemic outcomes.  This thesis project proposed to conduct a secondary analysis of 
data collected under the UM QI initiative.  Preliminary QI data shows that HbA1c levels are 
significantly lower in patients who perform six specific self-management habits on a regular 
basis.  This thesis project focused on a sub-analysis of those six behavioral habits and their 
relationship to time in range (rather than HbA1c) for pediatric patients who are on continuous 





Chapter 5. Methodology 
 
5.1 Study Design 
 
 A series of flowsheet elements were previously added to the electronic health record by 
the UM QI team.  Certified diabetes educators (CDE) and pediatric endocrinologists used these 
flowsheets to record information related to management habits at every diabetes clinic visit.  
This information was reported by the patient or downloaded from the diabetes device by clinical 
staff.  Pediatric patients with T1D often return to the clinic every three months for follow-up 
appointments.  Given the frequency of these routine visits, the data set for the thesis focus 
included information from 1,212 patients. 
 Retrospective chart reviews were conducted to obtain clinical data related to biomedical 
parameters (HbA1c values and time in range percentages), and behavioral  determinants 
(frequency of blood sugar testing, number of insulin bolus doses, patient usage of diabetes 
devices such as insulin pump or CGMs, etc.).  Data from the most recent clinic visit in which 
there was complete flowsheet data and available TIR values was included.  The six T1D habits 
that were reviewed in this project were as follows:  patient uses CGM or checks blood glucose 
four times/day; patient gives three or more insulin injections per day; patient uses an insulin 
pump; patient gives insulin before eating; blood glucose data has been reviewed for patterns at 
least once since the previous clinic visit; insulin doses have been changed (either by family or 
clinic) at least once since the previous clinic visit.  Individual scores were assigned to each self-
management habit.  One point was given for each habit that was performed.  A total score was 
then calculated for each patient representing the overall self-management habits performance 
level.  Total scores ranged from 0-6 points, reflecting the presence or absence of a behavior 
(refer to Table 3).  A higher habit score indicated that a patient was participating in more of the 
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habits; a lower score indicated less adherence to the chosen self-management behaviors.  Time in 
range values were extracted from the device download report (located either in the medical 
record or the patient’s online device account using shared log-in codes) and were reported as a 
percentage.   
 












Blood Glucose Testing Frequency on download 0 to 10 or more times Checks blood glucose 4 
times/day OR uses 
Continuous Glucose 
Monitor Uses CGM Yes, No 
2 Average number of bolus insulin doses per day on 
download (for pump) & patient report (for Multiple 
Daily Injections) 
0 to 10 or more times Gives 3 or more insulin 
injections per day 
3 Type of Intensive Therapy Multiple Daily Injections, 
Insulin Pump Therapy 
Uses insulin pump 
4 Timing of Insulin with meals “At least several minutes 
before the meal”, 
“Immediately before the 
meal”, “during or after the 
meal” 
Response of “At least 
several minutes before the 
meal” or  “Immediately 
before the meal” 
5 Number of times blood glucose or insulin data was 
downloaded and reviewed for blood glucose 
patterns since the last diabetes clinic visit: 
0 to 10 or more times Reviewed blood glucose 
data for patterns at least 
once since the last clinic 
visit 
6 Number of times insulin was adjusted by family or 
by diabetes team since the last diabetes clinic visit: 
0 to 10 or more times Changed insulin doses at 
least once since the last 




 The cohort used for analysis was a subpopulation of the UM pediatric endocrinology 
clinic.  Only patients with type 1 diabetes who use a CGM were included in the project data set.  
The total number of patients followed in the UM pediatric diabetes clinics during 2019 was 
1,212.  From this list, patients were excluded if they were non-CGM users which resulted in 720 
patients.  Of those remaining individuals, further exclusions were made if there was incomplete 
data for time in range in the download reports or medical records.  The final number included for 
review was 654 patients.  As shown in Table 4 below, the sample was nearly equally 
proportioned with both male (48.8%) and female (51.2%) patients, with an average age of 14.6 
years.  The predominate race for this cohort was white (88.4%).  Average time in range was 
40.4% with a standard deviation of approximately 20%; average total score for the six self-













Table 4.  Cohort characteristics 
  Total 
Characteristic n=654 
 Age (years), n(%)   
0-12 222 (33.9) 
13-17 265 (40.5) 
18+ 167 (25.5) 
Sex, n(%)   
Male 319 (48.8) 
Female 335 (51.2) 
Race, n(%)   
White 578 (88.4) 
Black 20 (3.1) 
Other 56 (8.6) 
Insurance   
Private 577 (88.2) 
Medicaid 77 (11.8) 
Time in Range (%) 40.4 ± 20.0 
HbA1c (%) 8.2 ± 1.4 
Habits Score_Total 4.1 ± 1.1 
CGM Type   
Dexcom 559 (85.5) 
Medtronic 60 (9.2) 
Libre 33 (5.0) 
Average Sensor Glucose 203.1 ± 45.5 
Average days in DL report: 14 
Avg. days of DL from HbA1c: 95.8 
 
5.1.2 Measurements 
 Demographic information was requested and included in the original data set.  Traits such 
as sex, race/ethnicity, type of insurance, and level of formal parental education were provided by 
the data repository.  
 Using the encounter date with a corresponding HbA1c value as a guide, data downloaded 
from a patient’s CGM on or near the encounter date was extracted from the medical record or 
directly from the user’s diabetes device account using shared log-in information.  A window of ± 
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90 days was applied when collecting data from the device downloads in cases where a download 
report was not available on the day of the clinic visit.  Time in range was reported as a 
percentage.  Average sensor glucose values, with standard deviations, were also collected from 
the same time point. 
 Diabetes management was quantified using the data for performances of the six self-
management habits which was pulled directly from the clinic flowsheets in the electronic 
medical record (see Appendix 5). One point was given for each habit performed (see Table 3).  A 
total score was calculated by summing the point values assigned to each habit, with a total of 6 
points being possible if a patient was adherent to all six self-management habits.   
 
5.2 Data Organization 
 Using a tabulated workbook in Microsoft Excel, data was imported from the repository.  
Protected Health Information (PHI) was removed as much as possible to reduce risk of a breach 
in confidentiality.  Appointment dates were the only remaining pieces of PHI, permitting the data 
set to be shared in a limited format.  Basic tables were created using the Descriptive Statistics 
feature of Excel’s data analysis package, or were developed manually.  A table was created using 
key demographic traits to quickly identify the cohort’s characteristics (see Table 4).  All versions 
of the data set were securely stored per the UM Data Use Agreement. 
 The data analysis plan was to use regression models to identify a relationship between the 
six self-management habits performed by pediatric patients with type 1 diabetes (T1D) and the 
association with optimal glycemic outcomes as measured by time in range.  The proposed 
relationship was that the self-management habits would predict TIR; higher scores from 6 habits 




 Measures were taken throughout the project to ensure data integrity.  The diagnosis of 
type 1 diabetes was based on clinician-defined diabetes, which is also a flowsheet item (see 
Appendix 4) that providers completed in the medical record.  This was used as a way to reduce 
error from misclassification based on diagnostic codes.  Regular meetings with Johns Hopkins 
University and University of Michigan faculty advisors were conducted to review data set 
results, evaluate the relevance of identifiable trends, address issues with interpreting downloaded 
data from the medical record, and to make adjustments if needed to the current practice. 
 
5.2.2 Limitations 
 Data related to the duration these patients have had type 1 diabetes was not readily 
available for the entire population which may have prevented use of some knowledge regarding 
the potential experience level this cohort had with managing diabetes.  Lack of previous research 
in this area was also a limitation to this project.  Much research is available for assessing 
relationships between self-management habits and glycemic outcomes using HbA1c values, but 
limited work has been done with time in range as the desired predicted outcome.   
  
5.3 Regulatory Compliance 
 Per the Johns Hopkins Medical Institution Institutional Review Board (JHMI IRB), no 
application was required for submission to any Johns Hopkins regulatory committee since the 
data set originated locally at the University of Michigan.  Thus, an application was submitted to 
the University of Michigan’s medical research review board.  The Institutional Review Boards of 
the University of Michigan Medical School (IRBMED) oversee human subjects research 
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conducted at the Medical School and Michigan Medicine. The University of Michigan served as 
the IRB of record for this project.  IRBMED granted a Letter of Exemption (Appendix 2) stating 




Chapter 6. Project Results and Discussion 
 
6.1 Overview 
 In general, there was a correlation detected between time and range and the six self-
management habits.  Patients who performed a self-management habit had higher time in range 
values than those who did not perform the habit.  Furthermore, time in range increased as more 
self-management habits were performed.  Although the impact that adherence of the behavioral 
habits had on time in range values was minor in a clinical sense, it was still quite statistically 
present.   
  
6.2 Data Analysis  
 The primary objective was to test for a relationship between the self-management habits 
and the association with optimal glycemic outcomes as measured by time in range. The variables 
were segmented into two groups:  predictive factors (HbA1c, average sensor glucose, scoring for 
self-management habits) and a criterion (time in range).  To assess the associations of each 
independent variable with time in range, a multivariate regression analysis was constructed first.  
To more clearly assess the effects of adherence to the six self-management habits on time in 
range, a regression analysis adjusted for only those two variables was conducted as it was the 
focus of the multivariate model. 
 
6.3 Results 
 Average time in range was 40.36% (±19.97) which was quite comparable to the mean 
TIR (41 ± 16%) Beck and colleagues found during their study to validate time in range as an 
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outcome measure for clinical trials.104  The target value for time in range was set to 60%, as this 
corresponds to a HbA1c target of 7.5%.  Total scores for the six habits averaged 4 points, and the 
average patient age was 14 years (refer to Fig.2).   
 
Figure 2.  Descriptive statistics 
 
  
 Metabolic control was noted to be affected by the performance of self-management habits 
and was slightly higher in patients 18 years of age and older versus any other pediatric age group 
sampled (Table 5).  This may be attributed to the increased independence with disease 
management that often accompanies the transition into adulthood.  Interestingly enough, even 
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though only 59.4% of the UM pediatric endocrinology population uses CGM, 18.8% of that 
cohort met the current time in range targets compared to the 32.9% of the total UM T1D 
population that currently meets the national standard for HbA1c levels.  The data did suggest that 
patients who performed a particular habit spent more time in glycemic target ranges than patients 
who did not perform the same self-management habit.  As shown in Figure 4, time in range 
percentages were consistently higher when a habit was performed compared to when a habit was 
not performed.  As the level of adherence increased reflected by a higher total habit score, time 
in range also increased (Fig. 3).  This gave rise to better metabolic control in the groups that were 
adherent to self-management behaviors as demonstrated by higher time in range values.  
 Children 18 years of age and older appeared to be better controlled as indicated by some 
of the highest TIR values amongst the cohort across all habits.  Male and females were shown to 
have comparable mean TIRs when a habit was performed.  Females, however, did tend to have 










































Time in Range vs. Total Habit Score
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 Although time in range was affected by the performance of a self-management habit, the 
observed difference between the sample means (41.5-31.4) by way of a t-Test was not 
convincing enough to say that the average time in ranges between patients that perform self-
management habits differs significantly from patients who do not perform the same habits 
suggesting that the practical value was small.  For this reason, the primary test for statistical 
significance was done using the regression analysis. 
 Results from the multivariate regression analysis were not statistically significant (refer 
to Appendix 6).  It is expected that the nature of the variables was too inter-connected to be 
successful in differentiating individual relationships.  Consequently, variables with high P-values 
were removed and a single linear regression analysis was performed (Fig. 5).  The Significance F 
value and associated P-value was less than 0.005, suggesting that these results were in fact 
statistically significant and that a predicting relationship was identified between the self-
management habits and time in range.  Conversely, the low R2 value (0.03) reflected a poor 
relationship between the two variables, despite the statistical significance.  Again, this may be 
attributed to the close nature of the dependent and independent variables.  A second linear 
regression analysis was conducted to evaluate the relationship between sex and time in range 








Figure 5.  Results of linear regression model 
 
  
 A correlation analysis (see Appendix 6.2) was also done in attempt to distinguish how 
strongly the relationship was between the six habits and time in range.  Again, the correlation 
coefficient (0.16) was too low to determine a meaningful degree of predictive ability that the six 
habits had on time in range values therefore the results were deemed irrelevant with regard to a 
clinical application.  
         
6.4 Descriptive Analysis 
 It was expected that the more adherent a patient with type 1 diabetes was to the self-
management habits, the more glucose levels would be within target ranges.  Therefore, the 
higher the total score for performing self-management habits would result in a higher percentage 
of time in range.  In general, this is what was observed in the full analysis. 
 
6.5 Limitations  
 Several of the dependent variables were highly intercorrelated thereby making it difficult 








df SS MS F Significance F
Regression 1 6800.644298 6800.644298 17.4914661 3.28086E-05
Residual 652 253496.1936 388.797843
Total 653 260296.8379
Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept 28.58124281 2.920182032 9.787486702 3.3735E-21 22.84714684 34.31533878 22.84714684 34.31533878
Habits Total (0-6pts) 2.852227769 0.68197915 4.182280014 3.2809E-05 1.513087313 4.191368224 1.513087313 4.191368224
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of the predictor variables to the criterion, it was difficult to ascertain which aspect of the 
behavioral traits were more note-worthy.    
 
6.6 Tests of hypotheses 
 The null hypothesis (H0) that there was no correlation between self-managed behavioral 
habits and time in range was rejected as there was a relationship noted between the predictor 
variables (behavioral traits) and the criterion (time in range) by a p-value of less than 0.005 and a 
positive correlation factor. 
 
 The alternative hypothesis (H1) which proposed that in pediatric patients with type 1 
diabetes who use a continuous glucose monitor, there is a positive correlation between adherence 
to six self-management behaviors and attaining time in range targets was retained.   
 
6.7 Alternatives Perspectives 
 
 Different statistical approaches with advanced software may have highlighted additional 
relationships among variables that were undetected by this sub-analysis of the UM CGM 
population.  There may have also been too many individual data points involved in the sub-
analysis to clearly distinguish key correlations.  
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Chapter 7. Recommendations and Discussion 
 
7.1 Overview 
 In order to ensure that the information discovered as a result of thesis project is utilized in 
a manner that promotes better metabolic control with increased rates of glycemic goal 
ascertainment in patients with type 1 diabetes, there are several elements that should first be 
taken into consideration. Among these are the feasibility to implement the addition of time in 
range metric evaluations during clinical reviews with patients, the availability of appropriate 
device usage to accurately record time in range data in a standardized manner, and the 
willingness of patients to comply with adherence to self-management behaviors, regardless of 
diabetes device accessibility. 
 
7.2 Applicability 
 If more focus can be placed on considering time in range as a glycemic metric when 
determining a patient’s level of metabolic success, patients would have more useful resources to 
enhance their diabetes education related to decision making in order to make immediate 
adjustments to their treatment regimens, thereby improving overall metabolic control.  As a 
result, we would expect a greater percentage of T1D patients meeting glycemic targets.   
 
7.3 Discussion of analysis 
 The data from this project reveals that there is a positive relationship between adherence 
to self-management habits and time in range as an outcome.  It is not being suggested that time 
in range be further studied as a replacement for HbA1c testing, but rather to be used more as a 
complementary metric since it has capabilities of capturing glycemic excursions that HbA1c is 
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unable to identify or predict.  It is evident that the current methods to assess metabolic control 
are not inclusive of characteristics that clearly reflect more of the glycemic profile.  As 
technology continues to evolve, clinicians and patients must be cognizant that adapting to newer 
methods of diabetes management must occur in order to continually improve metabolic control.  
Increasing access to diabetes devices, in conjunction with incorporating more reflective metrics 
into the evaluation of glycemic success is imperative. 
 
7.3.1 Post-hoc Analysis 
 Information collected from patient records indicating the length of time since diagnosis of 
type 1 diabetes might have provided insight to the level of experience and duration with 
managing diabetes that was present in this particular population.  It may have also been 
interesting to collect data regarding the level of independent diabetes management.  It is common 
for parents to solely manage their child’s diabetes until they reach a certain age of maturity and 
are thought to have a sufficient level of knowledge necessary to transition to a more independent 







Chapter 8. Conclusion 
  
8.1 Thesis Summary 
 The aim of this project was to see if the performance of six self-management habits had a 
perceived effect on time in range values.  While the clinical relationship between time in range 
and the six habits was not as profoundly exhibited as had been hoped, the presence of a positive 
relationship did still exist.  There were distinct differences observed between patients that 
performed a habit and patients that were noncompliant to the self-management behaviors with 





 Pediatric patients suffering from type 1 diabetes must make many decisions on a daily 
basis regarding the self-management habits that they will execute in order to control glycemic 
levels.  Research has shown that adhering to treatment plans and routinely participating in self-
management habits such as frequent self-monitoring of blood glucose, using continuous glucose 
monitors and/or insulin pumps, frequent bolusing and bolusing before meals, and reviewing 
diabetes data are associated with improved glycemic outcomes.105  This thesis project’s 
secondary analysis evaluated the prevalence of six habits in the pediatric T1D population at the 
University of Michigan and the relationship with glycemic outcomes as measured by time in 
range.  Results suggested that time in range has the potential to serve as an outcome metric for 
glycemic control in the future.   
 
                                                     
105McNally, K., Rohan, J., Shroff Pendley, J., Delamater, A., & Drotar, D. (2010). Executive Functioning, 






 Since the positive association between time in range and the six habits has been 
identified, it is possible to make stronger claims that this glucose metric is  clinically relevant and 
should be incorporated into evaluations of a patient’s success with diabetes control.  This 
information could be shared with clinicians, patients, researchers, and industry partners to 
educate and advance the technology behind diabetes management devices and to improve the 
quality of life for those diagnosed with diabetes. 
   
8.4 Recommendations for Future Research 
 The results of this study highlighted the need to consider the full spectrum of a patient's 
daily glycemic profile instead of only focusing on the three-month average, as currently 
measured by HbA1c levels.  “To fundamentally change clinical care with use of the new metrics, 
it would be important to demonstrate that the metrics relate to and predict clinical outcomes.  In 
this regard, longer-term studies relating to time spent within specific CGM glycemic ranges, 
diabetes complications, and other outcomes are required”.106 
Recommendations: 
 1. A comparative project exploring time in range in groups without CGM and those  
  with CGM would be valuable.  Depending on the results, healthcare policies  
  could be amended to push for the need for coverage of CGM devices since usage  
  has already been proven to reduce complications, and costs associated with T1D  
  management.  Research has shown that requesting patients without CGM   
                                                     
106 Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., . . . Phillip, M. (2019). Clinical 
Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International 
Consensus on Time in Range. Diabetes Care, 42(8), 1593-1603. doi:10.2337/dci19-0028 
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  devices check as frequently as necessary to obtain an accurate (real-time) value  
  for TIR is not cost effective, nor likely to be complied with by patients due to the  
  cost of testing supplies, the time required to check every few minutes, and the  
  inconvenience associated with more frequent self-monitoring. 
 
 2. A longitudinal study concentrating on self-management habits and glycemic  
  outcomes measured by time in range might be helpful in shedding light   
  on improvements in glycemic control and the factors that drive it over time.   
  Several time points could be used to assess the effect an increase in habit   
























Appendix 1.  Facilities and Resources 
 Resources from the University of Michigan Pediatric and Adult Endocrinology Quality 
Improvement (QI) Initiative and the MDiabetes Data Repository were used for this project, 
primarily in the form of a limited data set.  This thesis project was supervised by a faculty 
advisor from Johns Hopkins University and two pediatric endocrinologists that are also members 
of the QI team at the University of Michigan.   
 
JHU Faculty Advisor: Jeffery Kantor, PhD 
 Dr. Kantor received his Doctorate from Baylor University in Experimental Psychology 
and has over 40 years’ experience conducting, directing and evaluating research programs of all 
sizes.  He has been an Adjunct at the Graduate level for over 10 years teaching at various types 
of academic institutions. 
 
UM Faculty Advisors: Joyce M. Lee, MD, MPH and Inas H. Thomas, MD 
 Joyce is a Robert P. Kelch, MD, Research Professor of Pediatrics and Communicable 
Diseases, Associate Professor of Pediatrics and Communicable Diseases, Medical School and 
Associate Professor of Nutritional Sciences, School of Public Health.  Her areas of practice 
center on pediatric diabetes, pediatric obesity, and epidemiology. 
 Inas is a Clinical Associate Professor of Pediatrics and Communicable Diseases, 
Pediatric Diabetes Program Director and a member of the Pediatric Diabetes Transition Clinic.  


































































df SS MS F Significance F
Regression 3 154722.492 51574.16 317.5317479 6.6909E-127
Residual 650 105574.3459 162.4221
Total 653 260296.8379
Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept 112.6811189 3.900258574 28.89068 1.0885E-118 105.0224919 120.3397459 105.0224919 120.3397459
HbA1c (%) -0.456307402 0.534423708 -0.85383 0.393513314 -1.505712655 0.593097852 -1.505712655 0.593097852
Habits Total (0-6pts) -0.263763295 0.455549551 -0.579 0.562789602 -1.158289651 0.630763061 -1.158289651 0.630763061
Avg. Sensor Glucose (mg -0.331917492 0.016866144 -19.6795 5.47444E-68 -0.365036194 -0.298798789 -0.365036194 -0.298798789
64  






















df SS MS F Significance F
Regression 1 293.8185035 293.8185035 0.736797844 0.391004015
Residual 652 260003.0194 398.7776371
Total 653 260296.8379
Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept 39.67398119 1.118072733 35.48425788 2.1322E-154 37.47852341 41.869439 37.47852341 41.86943897
Sex          Code 1.340944182 1.562199617 0.858369294 0.391004015 -1.72660518 4.40849354 -1.72660518 4.408493544
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HbA1c (%) Habits Total (0-6pts)
Avg. Sensor Glucose 
(mg/dL) Time in Range (%)
HbA1c (%) 1
Habits Total (0-6pts) -0.244873872 1
Avg. Sensor Glucose (mg/dL) 0.753574537 -0.224979134 1
Time in Range (%) -0.593689026 0.16163693 -0.770589423 1
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